MAKING-SCIENCE
22.1.2024 16:01:32 CET | Business Wire | Press release
Making Science, a technology company specialising in innovation and digital acceleration, has today announced the launch of Gauss Cookie Deprecation Impact Tool, the first and only solution on the market designed to measure in real time what impact the loss of third-party cookies will have on companies' conversion rate to sales.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240122293551/en/
(Photo: Business Wire)
This innovative tool comes at a key moment for the industry, following the announcement of Google's elimination of third-party cookies, scheduled for the second half of 2024. The Gauss Cookie Deprecation Impact Tool will provide Making Science customers with accurate percentage data to confirm how this loss of information will affect their business. In other words, for the first time, companies will have access to an unprecedented assessment that provides real data on the percentage of users who visit websites and applications without cookies, corroborating the effect on their marketing strategies.
The tool has already yielded very significant data for a selection of Making Science clients, measuring that the absence of third-party cookies will lead to a 30% drop in their conversion rates.
Real-time data thanks to technological innovation
This new platform is essential for companies that want to be prepared for the cookieless transformation of the digital ecosystem. Thanks to technological innovation and high capabilities in data analysis, Making Science will enable organisations to effectively identify how to redesign their marketing strategies, and optimise their performance in the face of this changing landscape.
With this launch, Making Science reaffirms its pioneering position in the development of innovative technological solutions. José Antonio Martínez Aguilar, CEO and Founder of Making Science, comments: "Staying ahead in a constantly changing digital environment is not an easy task, for that, it is essential to bet on innovation every day. Undoubtedly, the key is to have the ability to anticipate and come up with solutions such as Gauss Cookie Deprecation Impact Tool. This solution not only responds to the challenge of the loss of third-party cookies, but also offers companies the opportunity to anticipate and make strategic decisions to face a new landscape based on first-party data".
Gauss, the origin of the cutting edge
This new tool from Making Science is part of Gauss, a suite of technology solutions based on First Party Data and Artificial Intelligence for decision-making in key marketing and sales processes.
About Making Science
Making Science is a digital acceleration company with more than 1200 employees and a presence and technological development in 14 markets: Spain, Portugal, Mexico, Colombia, France, Italy, UK, Ireland, Sweden, Denmark, Norway, Germany, Georgia and USA. As a consulting partner of Local Planet, the world's largest network of independent media agencies, Making Science offers digital, technology and performance marketing services to an international audience. The areas in which Making Science operates are digital marketing and MarTech, software and cloud and artificial intelligence and SaaS, with a firm commitment to innovation.
As part of its commitment to innovation, Making Science offers its clients end-to-end capabilities required for consulting, development, integration and maintenance of advanced IT solutions that offer maximum scalability, cost-effectiveness and efficiency. In addition, it has a global network of delivery hubs that drive job creation and the availability of highly qualified technological talent for the development of projects that accelerate transformation and modernization.
Making Science participates in various ESG initiatives, including the Climate Pledge, the United Nations Global Compact and the Pledge1% initiative, supporting non-profit organisations in its community with a strong commitment that will have a great impact in the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122293551/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 18:00:00 CET | Press release
New feature lets members follow friends and family, share performance and health insights, and celebrate life's moments together WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release
Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom